Over the past 20 years, Michael held various executive positions in R&D and commercial roles at Roche and Eli Lilly and co-founded a biotech company.
In his last role at Roche, Michael was responsible for establishing sustainable innovative pricing models with national payers in over 20 major markets. Previously he set-up and led research and translational medicine units at both Roche and Eli Lilly and led the innovation sourcing activities with global academic centers of excellence.
Michael served on the board of several start-up biotech and medical technology companies as well as R&D subsidiaries of large pharmaceutical companies.
Michael holds a PhD in biochemistry and immunology from the University of Lausanne (summa cum laude, Marc Dufour Prize winner 1997) and an MBA from IMD.